Skip to main content

Our Team

Meet the visionaries and scientists driving the future of longevity research and cancer therapeutics at 199 Bio.

Leadership

Boris Djordjevic - Founder & CEO

Boris Djordjevic

Founder & CEO

Founder of the 199 group of companies, developing breakthrough therapies in cellular reprogramming and epigenetic treatments for aging and cancer.

Antonia Schultze-Mosgau - Chief Operating Officer

Antonia Schultze-Mosgau

Chief Operating Officer

Serial entrepreneur and longevity expert, translating cutting-edge research into scalable health applications. Oxford All-Innovate Award winner.

Dr. Avi Roy - Chief Scientific Officer

Dr. Avi Roy

Chief Scientific Officer

Oxford biomedical scientist pioneering cellular rejuvenation. President of Biogerontology Research Foundation and discoverer of 12 novel geroprotective drugs.

Dr. Qinghua Lyu - Chief Technical Officer

Dr. Qinghua Lyu

Chief Technical Officer

Drug development expert from National University of Singapore leading chemical sciences division. The chemistry genius behind our breakthrough senolytic compounds.

ZY

Zico Yip

Chief Operating Officer

General Manager of our laboratories and manufacturing facilities, bringing deep biotech experience with successful fundraising, exits, and investments.

Join Our Team

We're always looking for exceptional talent to join our mission of revolutionizing cancer treatment and extending healthy human lifespan.